Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study

Background: Few data are available on metastatic colorectal cancer (mCRC) treated with late-line regorafenib monotherapy or combined with other therapies. This study thus aimed to examine regorafenib combined with immune checkpoint inhibitors (ICIs) compared with regorafenib monotherapy in patients...

ver descrição completa

Detalhes bibliográficos
Autores: Chen, Can, Luo, Xi, Tang, Wenhua, Geng, Haofei, Martínez-Pérez, Julia, Price, Timothy, Kang, Lili, Lu, Honglian, Zhang, Yanling
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/386661
Acesso em linha:http://hdl.handle.net/10261/386661
https://api.elsevier.com/content/abstract/scopus_id/85203077622
Access Level:Acceso aberto
Palavra-chave:Colorectal cancer (CRC)
Immune checkpoint inhibitors (ICIs)
Metastatic
Prognosis
Regorafenib
id ES_4d7bb1b58398c75dd5c66e4e8fe3c1e1
oai_identifier_str oai:digital.csic.es:10261/386661
network_acronym_str ES
network_name_str España
repository_id_str
spelling Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort studyChen, CanLuo, XiTang, WenhuaGeng, HaofeiMartínez-Pérez, JuliaPrice, TimothyKang, LiliLu, HonglianZhang, YanlingColorectal cancer (CRC)Immune checkpoint inhibitors (ICIs)MetastaticPrognosisRegorafenibBackground: Few data are available on metastatic colorectal cancer (mCRC) treated with late-line regorafenib monotherapy or combined with other therapies. This study thus aimed to examine regorafenib combined with immune checkpoint inhibitors (ICIs) compared with regorafenib monotherapy in patients with advanced CRC. Methods: This single-center retrospective cohort study included patients with advanced CRC who experienced recurrence and progression after standard first- and second-line treatments treatment from November 2018 to December 2021. The patients received regorafenib plus ICIs or regorafenib monotherapy. Treatment response was evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST). Overall survival (OS) and progression-free survival (PFS) were analyzed via multivariate analysis. Results: The combined group and the monotherapy group included 30 and 43 patients, respectively. The median OS (13.7 vs. 10.1 months; P=0.10) and PFS (4 vs. 3.6 months; P=0.32) were not significantly different between the two groups. In males, the median OS was significantly longer in the combined group compared with the monotherapy group (not reached vs. 8.03 months; P=0.02), but the median PFS showed no significant difference (7.23 vs. 3.90 months; P=0.16). There was no significant difference in OS (P=0.71) or PFS (P=0.89) in females. Eastern Cooperative Oncology Group performance status (ECOG PS) 1 [vs. 0; hazard ratio (HR) =3.13, 95% confidence interval (CI): 1.61–6.10; P<0.001] was independently associated with PFS. ECOG PS 1 (vs. 0; HR =3.63, 95% CI: 1.54–8.56; P=0.003) and combined therapy (vs. monotherapy; HR =0.47, 95% CI: 0.22–0.99; P=0.048) were associated with OS. Conclusions: Regorafenib combined with ICIs led to numerically longer PFS and significantly prolonged OS in patients with mCRC compared to regorafenib monotherapy, especially in male patients.Peer reviewedAME PublishingMartínez-Pérez, Julia [0000-0003-0634-4974]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/386661https://api.elsevier.com/content/abstract/scopus_id/85203077622reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://dx.doi.org/10.21037/jgo-24-468Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3866612026-05-22T06:33:51Z
dc.title.none.fl_str_mv Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
title Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
spellingShingle Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
Chen, Can
Colorectal cancer (CRC)
Immune checkpoint inhibitors (ICIs)
Metastatic
Prognosis
Regorafenib
title_short Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
title_full Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
title_fullStr Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
title_full_unstemmed Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
title_sort Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
dc.creator.none.fl_str_mv Chen, Can
Luo, Xi
Tang, Wenhua
Geng, Haofei
Martínez-Pérez, Julia
Price, Timothy
Kang, Lili
Lu, Honglian
Zhang, Yanling
author Chen, Can
author_facet Chen, Can
Luo, Xi
Tang, Wenhua
Geng, Haofei
Martínez-Pérez, Julia
Price, Timothy
Kang, Lili
Lu, Honglian
Zhang, Yanling
author_role author
author2 Luo, Xi
Tang, Wenhua
Geng, Haofei
Martínez-Pérez, Julia
Price, Timothy
Kang, Lili
Lu, Honglian
Zhang, Yanling
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Martínez-Pérez, Julia [0000-0003-0634-4974]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Colorectal cancer (CRC)
Immune checkpoint inhibitors (ICIs)
Metastatic
Prognosis
Regorafenib
topic Colorectal cancer (CRC)
Immune checkpoint inhibitors (ICIs)
Metastatic
Prognosis
Regorafenib
description Background: Few data are available on metastatic colorectal cancer (mCRC) treated with late-line regorafenib monotherapy or combined with other therapies. This study thus aimed to examine regorafenib combined with immune checkpoint inhibitors (ICIs) compared with regorafenib monotherapy in patients with advanced CRC. Methods: This single-center retrospective cohort study included patients with advanced CRC who experienced recurrence and progression after standard first- and second-line treatments treatment from November 2018 to December 2021. The patients received regorafenib plus ICIs or regorafenib monotherapy. Treatment response was evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST). Overall survival (OS) and progression-free survival (PFS) were analyzed via multivariate analysis. Results: The combined group and the monotherapy group included 30 and 43 patients, respectively. The median OS (13.7 vs. 10.1 months; P=0.10) and PFS (4 vs. 3.6 months; P=0.32) were not significantly different between the two groups. In males, the median OS was significantly longer in the combined group compared with the monotherapy group (not reached vs. 8.03 months; P=0.02), but the median PFS showed no significant difference (7.23 vs. 3.90 months; P=0.16). There was no significant difference in OS (P=0.71) or PFS (P=0.89) in females. Eastern Cooperative Oncology Group performance status (ECOG PS) 1 [vs. 0; hazard ratio (HR) =3.13, 95% confidence interval (CI): 1.61–6.10; P<0.001] was independently associated with PFS. ECOG PS 1 (vs. 0; HR =3.63, 95% CI: 1.54–8.56; P=0.003) and combined therapy (vs. monotherapy; HR =0.47, 95% CI: 0.22–0.99; P=0.048) were associated with OS. Conclusions: Regorafenib combined with ICIs led to numerically longer PFS and significantly prolonged OS in patients with mCRC compared to regorafenib monotherapy, especially in male patients.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/386661
https://api.elsevier.com/content/abstract/scopus_id/85203077622
url http://hdl.handle.net/10261/386661
https://api.elsevier.com/content/abstract/scopus_id/85203077622
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://dx.doi.org/10.21037/jgo-24-468
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv AME Publishing
publisher.none.fl_str_mv AME Publishing
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407694959411200
score 15,812429

Registros relacionados